Two first-line therapies in the treatment of mild asthma: Use of peak flow variability as a predictor of effectiveness

Annals of Allergy, Asthma and Immunology

Volumn 82, Issue 5, 1999, Pages 497-503

  Nathan, Robert A ^a   Minkwitz, Margaret C ^b   Bonuccelli, Catherine M ^b  

^a Asthma & Allergy Associates PC and Research Center   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CROMOGLYCATE DISODIUM; THEOPHYLLINE; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0033013161     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62728-7     Document Type: Article

References (20)

1. National Heart Lung and Blood Institute. Executive Summary: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health publication; 1997:No. 97-4051.
2. Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (ACCOLATE™) or cromolyn sodium (INTAL®) in patients with mild to moderate asthma [Abstract]. J Allergy Clin Immunol 1995;5(1)Part 2:Abs990.
3. Valletta EA, Comis A, Del Col G, et al. Peak expiratory flow variation and bronchial hyperresponsiveness in asthmatic children during periods of antigen avoidance and reexposure. Allergy 1995;50:366-369.
4. Jamison JP, McKinley RK. Validity of peak expiratory flow rate variability for the diagnosis of asthma. Clin Sci 1993;85:367-371.
5. Neukirch F, Liard R, Segala C, et al. Peak expiratory flow variability and bronchial hyperresponsiveness to methacholine. An epidemiologic study in 117 workers. Am Rev Respir Dis 1992;146:71-75.
6. Quackenboss JJ, Lebowitz MD, Krzyzanowski M. The normal range of diurnal changes in peak expiratory flow rates. Am Rev Respir Dis 1991; 143:323-330.
7. Enright PL, Burchette RJ, Peters JA, et al. Peak flow lability. Association with asthma and spirometry in an older cohort. Chest 1997;112:895-901.
8. Chervinsky P, van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild-to-moderate asthma. The fluticasone propionate asthma study group. J Allergy Clin Immunol 1994;94: 676-683.
9. Dahl R, Lundback B, Malo JL, et al. A dose ranging study of fluticasone propionate in adult patients with moderate asthma. International study group. Chest 1993;104:1352-1358.
10. LeBlanc P, Mink S, Keistinen T, et al. A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma. Allergy 1994;49:380-385.
11. Dekker FW, Dieleman FE, Kaptein AA, Mulder JD. Compliance with pulmonary medication in general practice. Eur Respir J 1993;6:886-890.
12. Bousquet J. Factors affecting compliance in patients with mild asthma. Eur Respir Rev 1997;7:318-320.
13. Mann M, Eliasson O, Patel K, Zu Wallack RL. A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. Chest 1992; 101:496-499.
14. Coutts JAP, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992;67:332-333.
15. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment of technique. JAMA 1989;261:3277-3277.
16. Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994;32: 452-457.
17. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-1352.
18. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-1063.
19. Fish JE, Kemp JP, Lockey RF, et al. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clinical Therapeutics 1997;19:675-690.
20. Drug Facts and Comparisons. St. Louis, MO: A Wolters Kluwer Company; 1997.